BALTIMORE (WJZ) — A Maryland-based company has signed a $174 million agreement to expand production of a coronavirus vaccine candidate.
Gaithersburg-based Emergent BioSolutions announced on Monday it had signed the agreement to develop and manufacture AstraZeneca’s possible COVID-19 vaccine.READ MORE: $30K Reward Offered For Information In Efraim Gordon's Fatal Shooting
Under the agreement, manufacturing will begin at Emergent’s Bayview facility in Baltimore.
CORONAVIRUS RESOURCES:READ MORE: What Parents Need To Know About COVID Vaccines For Preteens, Teens As FDA Expected To Give Pfizer OK
- Coronavirus Resources: How To Get Help In Maryland
- TIMELINE: Coronavirus In Maryland, Tracking The Spread
- Latest coronavirus stories from WJZ
- Latest CDC Guidelines
AstraZeneca, which is developing the vaccine with Oxford University, has signed Emergent and other companies to mass-produce the vaccine if it works.
The vaccine is one of several candidates supported by Operation Warp Speed, the federal government’s program to accelerate the development, manufacturing and distribution of COVID-19 vaccines with the goal of making them available by early 2021.MORE NEWS: Don't Bug Out About Cicadas: University of Md. Expert Answers Questions